Evidence map›Paper›PMID 36408305›Full record

ArticleCureus2022

Mesenteric Vasculitis and Urinary System Involvement Presenting As the Initial Manifestations of Systemic Lupus Erythematosus Treated Successfully With Glucocorticoids and Rituximab: A Case Report.

Roaa Alsolaimani

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Roaa AlsolaimaniInternal Medicine, King Abdulaziz University, Jeddah, SAU.
King Abdulaziz University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We describe a case of systemic lupus erythematosus (SLE) presenting initially with mesenteric vasculitis and urinary system involvement without any other SLE clinical features and a weakly positive antinuclear antibody on initial testing. She is a 15-year-old healthy female who presented with severe abdominal pain, diarrhea, vomiting, and weight loss for more than one month. She later developed cystitis and bilateral hydronephrosis. Her repeated autoantibody panel and computed tomography of the abdomen were diagnostic for mesenteric vasculitis related to SLE, and a colonic biopsy showed occlusive thromboangiopathy related to associated antiphospholipid antibody syndrome. She responded well to intravenous methylprednisolone, rituximab, and anticoagulation. Mycophenolate mofetil and hydroxychloroquine were used later for maintenance treatment. Lupus mesenteric vasculitis (LMV) is rare but a serious, potentially life-threatening, gastrointestinal complication associated with SLE. Clinical features are not very specific, making them challenging to diagnose. Thus, early diagnosis requires a high index of suspension especially in cases presenting with gastrointestinal symptoms without a previously established diagnosis of SLE. LMV occurs as an initial presentation of SLE in children more than adults. So, it is wise to investigate children presenting with gastrointestinal manifestations and involvement of other organs especially the urinary system thoroughly with autoantibodies and abdominal imaging to rule out or confirm the diagnosis of LMV and to start treatment early and aggressively.

Indexed as

abdominal paingastrointestinal vasculitislupus mesenteric vasculitisrituximabsystemic lupus erythematosus

Identifiers

PMID36408305
PMCPMC9661678
OpenAlexW4309000678

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.